Diamedica Stock Soars 10.2% on Major Shareholder's Purchase

On July 28, 2025, Diamedica's stock surged by 10.2% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Jan Stahlberg, a major shareholder of Diamedica Therapeutics, recently acquired 1,542,857 shares at an average price of $3.50 each, demonstrating a strong vote of confidence in the company's future prospects. This substantial purchase not only increased his total ownership but also sent a positive signal to the market about the company's potential.

In addition to Stahlberg's investment, 35 institutional investors have also added shares of Diamedica Therapeutics, further bolstering the company's financial position. This collective interest from both individual and institutional investors underscores the growing optimism surrounding Diamedica's strategic initiatives and market opportunities.